---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-336078"
form_type: "8-K"
ticker: "TNYA"
cik: "0001858848"
company_name: "Tenaya Therapeutics, Inc."
filed_at: "2021-11-22T23:59:59+00:00"
generated_at: "2026-06-28T06:17:33.455455+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Tenaya Therapeutics appoints Dr. June Lee to board; Dr. JeenJoo Kang resigns

## Summary
- Dr. June Lee appointed as Class III director, term expiring at 2024 annual meeting.
- Dr. Lee receives annual cash retainer of $35,000 and stock option grant with ~$320,000 fair value.
- Dr. Lee most recently CEO of Esker Therapeutics; previously EVP at MyoKardia advancing cardiomyopathies.
- Dr. JeenJoo Kang resigned voluntarily, not due to any disagreement, to focus on CEO role at Appia Bio.
- Company highlights transition to clinical-stage and Dr. Lee's relevant development experience.

## SEC filing metadata
- accession: 0001193125-21-336078
- form_type: 8-K
- ticker: TNYA
- cik: 0001858848
- company_name: Tenaya Therapeutics, Inc.
- filed_at: 2021-11-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858848/000119312521336078/0001193125-21-336078-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858848/000119312521336078/d255712d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-336078
- JSON: https://secwatch.observer/filing/0001193125-21-336078.json
- Plain text: https://secwatch.observer/filing/0001193125-21-336078.txt

## Key facts
- Executive change
  JeenJoo Kang resigned as Director at Tenaya Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On November 17, 2021, JeenJoo Kang, Ph.D., submitted her resignation as a director of Tenaya Therapeutics, Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1858848/000119312521336078/0001193125-21-336078-index.htm
- Executive change
  June Lee was appointed as Director at Tenaya Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: On November 19, 2021, the Board appointed June Lee, M.D., to serve as a Class III director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1858848/000119312521336078/0001193125-21-336078-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.